![]() |
|
|
Vol. 296, Issue 2, 650-658, February 2001
School of Fisheries Sciences, Kitasato University, Kesen-gun
Sanriku-cho, Iwate, Japan (R.S., C.O., H.K.); Molecular Neurobiology
Laboratory, The Salk Institute for Biological Studies, La Jolla,
California (G.T.S., T.G., A.C., A.G.); and the Suntory Institutes for
Bioorganic Research (K.S.) and for Biomedical Research (Y.T-H.),
Mishima-gun, Osaka, Japan
Dysiherbaine (DH) is a marine sponge-derived amino acid that causes
seizures upon injection into mice. In this report we investigate the
behavioral effects and characterize the pharmacological activity of DH.
DH induced convulsive behaviors in mice with ED50 values of
13 pmol/mouse, i.c.v. and 0.97 mg/kg, i.p. In rat brain synaptic membranes DH displaced binding of [3H]kainic acid (KA)
and [3H]
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) with Ki values of 26 and 153 nM,
respectively; in contrast, DH did not displace the
N-methyl-D-aspartic acid (NMDA) receptor ligand [3H]CGS-19755. DH displaced [3H]KA
from recombinant GluR5 and GluR6 kainate receptor subunits expressed in
HEK293 cells with Ki values of 0.74 and 1.2 nM, respectively. In whole-cell voltage-clamp recordings from cultured
rat hippocampal neurons, DH evoked inward currents from both AMPA and
KA receptors with EC50 values of 9.7 µM and 210 nM,
respectively. AMPA receptor currents were blocked by GYKI 53655, whereas KA receptor currents were blocked by
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). Surprisingly, in calcium
imaging experiments we found that DH also activated recombinant mGluR5
receptors but did not activate mGluR1 receptors. DH did not activate
glutamate transporters or
-aminobutyric acid A (GABAA)
receptors. These results indicate that DH is a potent non-NMDA-type
agonist with very high affinity for KA receptors, as well as a
subtype-selective mGluR agonist. DH possesses the most potent
epileptogenic activity among the amino acids yet identified. This novel
excitatory amino acid may prove useful for evaluating the physiological
and pathological roles of non-NMDA receptors, especially KA receptors,
in the central nervous system.
This article has been cited by other articles:
![]() |
L. L. Lash, J. M. Sanders, N. Akiyama, M. Shoji, P. Postila, O. T. Pentikainen, M. Sasaki, R. Sakai, and G. T. Swanson Novel Analogs and Stereoisomers of the Marine Toxin Neodysiherbaine with Specificity for Kainate Receptors J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 484 - 496. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Sanders, O. T. Pentikainen, L. Settimo, U. Pentikainen, M. Shoji, M. Sasaki, R. Sakai, M. S. Johnson, and G. T. Swanson Determination of Binding Site Residues Responsible for the Subunit Selectivity of Novel Marine-Derived Compounds on Kainate Receptors Mol. Pharmacol., June 1, 2006; 69(6): 1849 - 1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Sanders, K. Ito, L. Settimo, O. T. Pentikainen, M. Shoji, M. Sasaki, M. S. Johnson, R. Sakai, and G. T. Swanson Divergent Pharmacological Activity of Novel Marine-Derived Excitatory Amino Acids on Glutamate Receptors J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1068 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shimamoto, R. Sakai, K. Takaoka, N. Yumoto, T. Nakajima, S. G. Amara, and Y. Shigeri Characterization of Novel L-threo-{beta}-Benzyloxyaspartate Derivatives, Potent Blockers of the Glutamate Transporters Mol. Pharmacol., April 1, 2004; 65(4): 1008 - 1015. [Abstract] [Full Text] |
||||